Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China
Abstract The phase III NOTABLE trial has revealed that nimotuzumab plus gemcitabine achieves greater clinical benefit in the first-line treating K-Ras wild type locally advanced (LA) or metastatic pancreatic cancer (mPC), compared to gemcitabine. Hence, herein, we examined the cost-efficiency of int...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-90960-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849724037048041472 |
|---|---|
| author | Rong Long Hao Guo Kun Chen |
| author_facet | Rong Long Hao Guo Kun Chen |
| author_sort | Rong Long |
| collection | DOAJ |
| description | Abstract The phase III NOTABLE trial has revealed that nimotuzumab plus gemcitabine achieves greater clinical benefit in the first-line treating K-Ras wild type locally advanced (LA) or metastatic pancreatic cancer (mPC), compared to gemcitabine. Hence, herein, we examined the cost-efficiency of introducing nimotuzumab to gemcitabine, relative to gemcitabinealone, in first-line K-Ras wild type LA or mPC therapy from a Chinese payer perspective. We generated an exhaustive decision-analytical Markov model using three exclusive health states to incorporate both clinical and economic consequences of nimotuzumab plus gemcitabine versus gemcitabine alone as first-line therapy patients with K-Ras wild type LA or mPC. Using a 10-year lifetime horizon, we assessed the total medical expenditure, quality-adjusted life years (QALYs), and incremental cost‒effectiveness ratio (ICER) as the primary surrogate outcomes of our model. Sensitivity analyses were conducted via alteration of internally tweakable parameters, and further subgroup analyses were conducted as needed. The overall health surrogate outcomes were 2.94 QALYs ($215,799) among patients with nimotuzumab plus gemcitabine and 1.83 QALYs ($86,039) among patients with gemcitabine alone (ICER value, $117,263/QALY; Incremental net health benefit [INHB] value, − 2.46/QALY). Based on our sensitivity analysis, among all parameters, progression-free survival (PFS) utility was of utmost importance, and it exerted a considerable impact on our model. The ICER consistently well exceeded the willingness-to-pay (WTP) threshold and negative INHBs were observed across all patient subcategories with zero alteration recorded as cost-effective in the subgroup analyses. Nimotuzumab plus gemcitabine, relative to gemcitabine alone, is not a cost-effective first-line treatment among patients with K-Ras wild type LA or mPC at the current prices offered in China. |
| format | Article |
| id | doaj-art-9f472f9a4b074ff5ae8d95d9ac1c8e58 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-9f472f9a4b074ff5ae8d95d9ac1c8e582025-08-20T03:10:52ZengNature PortfolioScientific Reports2045-23222025-02-011511910.1038/s41598-025-90960-xCost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in ChinaRong Long0Hao Guo1Kun Chen2Department of Oncology, Xiangya Hospital, Central South UniversityDepartment of Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan UniversityDepartment of Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan UniversityAbstract The phase III NOTABLE trial has revealed that nimotuzumab plus gemcitabine achieves greater clinical benefit in the first-line treating K-Ras wild type locally advanced (LA) or metastatic pancreatic cancer (mPC), compared to gemcitabine. Hence, herein, we examined the cost-efficiency of introducing nimotuzumab to gemcitabine, relative to gemcitabinealone, in first-line K-Ras wild type LA or mPC therapy from a Chinese payer perspective. We generated an exhaustive decision-analytical Markov model using three exclusive health states to incorporate both clinical and economic consequences of nimotuzumab plus gemcitabine versus gemcitabine alone as first-line therapy patients with K-Ras wild type LA or mPC. Using a 10-year lifetime horizon, we assessed the total medical expenditure, quality-adjusted life years (QALYs), and incremental cost‒effectiveness ratio (ICER) as the primary surrogate outcomes of our model. Sensitivity analyses were conducted via alteration of internally tweakable parameters, and further subgroup analyses were conducted as needed. The overall health surrogate outcomes were 2.94 QALYs ($215,799) among patients with nimotuzumab plus gemcitabine and 1.83 QALYs ($86,039) among patients with gemcitabine alone (ICER value, $117,263/QALY; Incremental net health benefit [INHB] value, − 2.46/QALY). Based on our sensitivity analysis, among all parameters, progression-free survival (PFS) utility was of utmost importance, and it exerted a considerable impact on our model. The ICER consistently well exceeded the willingness-to-pay (WTP) threshold and negative INHBs were observed across all patient subcategories with zero alteration recorded as cost-effective in the subgroup analyses. Nimotuzumab plus gemcitabine, relative to gemcitabine alone, is not a cost-effective first-line treatment among patients with K-Ras wild type LA or mPC at the current prices offered in China.https://doi.org/10.1038/s41598-025-90960-xK-Ras wild typeLocally advanced or metastatic pancreatic cancerNimotuzumabGemcitabineCost-effectivenessFirst-line treatment |
| spellingShingle | Rong Long Hao Guo Kun Chen Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China Scientific Reports K-Ras wild type Locally advanced or metastatic pancreatic cancer Nimotuzumab Gemcitabine Cost-effectiveness First-line treatment |
| title | Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China |
| title_full | Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China |
| title_fullStr | Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China |
| title_full_unstemmed | Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China |
| title_short | Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China |
| title_sort | cost effectiveness analysis of nimotuzumab combined with gemcitabine for k ras wild type locally advanced or metastatic pancreatic cancer in china |
| topic | K-Ras wild type Locally advanced or metastatic pancreatic cancer Nimotuzumab Gemcitabine Cost-effectiveness First-line treatment |
| url | https://doi.org/10.1038/s41598-025-90960-x |
| work_keys_str_mv | AT ronglong costeffectivenessanalysisofnimotuzumabcombinedwithgemcitabineforkraswildtypelocallyadvancedormetastaticpancreaticcancerinchina AT haoguo costeffectivenessanalysisofnimotuzumabcombinedwithgemcitabineforkraswildtypelocallyadvancedormetastaticpancreaticcancerinchina AT kunchen costeffectivenessanalysisofnimotuzumabcombinedwithgemcitabineforkraswildtypelocallyadvancedormetastaticpancreaticcancerinchina |